Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$113.87 USD
-0.68 (-0.59%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $113.78 -0.09 (-0.08%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Company Summary
Dublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus on neuroscience and oncology. The company derives most of its revenues from its sleep disorder drugs — Xywav and Xyrem. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. Xywav is also approved for treating idiopathic hypersomnia (IH).
Other drugs in the company’s neuroscience portfolio include — Epidiolex (Epidyolex in ex-U.S.) and Sativex. Epidiolex, a cannabidiol (...
Company Summary
Dublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus on neuroscience and oncology. The company derives most of its revenues from its sleep disorder drugs — Xywav and Xyrem. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. Xywav is also approved for treating idiopathic hypersomnia (IH).
Other drugs in the company’s neuroscience portfolio include — Epidiolex (Epidyolex in ex-U.S.) and Sativex. Epidiolex, a cannabidiol (CBD), is approved for treating seizures associated with three rare and severe forms of epilepsy — Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) and tuberous sclerosis complex (TSC) — in patients aged one year and older.
Sativex is an oral nabiximol approved in the United Kingdom and Canada for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis (MS).
Jazz’s oncology portfolio includes two older drugs — Defitelio for the treatment of patients with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT) and Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML). The company received approval for two new drugs — Zepzelca (lurbinectedin) and Rylaze (JZP458) — in 2020 and 2021, respectively. While Zepzelca is approved for metastatic small cell lung cancer (SCLC), Rylaze is approved for treating acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients who have developed hypersensitivity to E. coli-derived asparaginase. Rylaze is marketed in Europe under the trade name Enrylaze.
Jazz has also bolstered its commercial portfolio and pipeline through acquisitions. In 2021, Jazz acquired British cannabinoid drug company GW Pharmaceuticals, adding Epidiolex and Sativex to its portfolio.
In 2023, sales rose 5% year over year to $3.8 billion. Total revenues included $2.8 billion from the neuroscience franchise (including royalty revenues from high sodium oxybate authorized generics) and $1 billion from the oncology franchise.
General Information
Jazz Pharmaceuticals PLC
FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD
DUBLIN, L2 D04
Phone: 011-353-1634-7800
Fax: 353-1634-7850
Web: http://www.jazzpharma.com
Email: investorinfo@jazzpharma.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 5.49 |
Current Year EPS Consensus Estimate | 19.53 |
Estimated Long-Term EPS Growth Rate | 5.00 |
Exp Earnings Date | 11/13/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 114.55 |
52 Week High | 146.70 |
52 Week Low | 99.06 |
Beta | 0.58 |
20 Day Moving Average | 654,861.50 |
Target Price Consensus | 175.50 |
4 Week | 3.95 |
12 Week | 7.97 |
YTD | -7.42 |
4 Week | -0.39 |
12 Week | 0.33 |
YTD | -20.26 |
Shares Outstanding (millions) | 61.75 |
Market Capitalization (millions) | 7,031.93 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 5.83 |
Trailing 12 Months | 6.38 |
PEG Ratio | 1.17 |
vs. Previous Year | 21.93% |
vs. Previous Quarter | 135.86% |
vs. Previous Year | 6.95% |
vs. Previous Quarter | 13.51% |
Price/Book | 1.87 |
Price/Cash Flow | 4.09 |
Price / Sales | 1.80 |
6/30/24 | 28.65 |
3/31/24 | 27.86 |
12/31/23 | 31.27 |
6/30/24 | 9.29 |
3/31/24 | 8.91 |
12/31/23 | 9.81 |
6/30/24 | 2.37 |
3/31/24 | 2.27 |
12/31/23 | 2.24 |
6/30/24 | 2.02 |
3/31/24 | 1.90 |
12/31/23 | 1.85 |
6/30/24 | 26.90 |
3/31/24 | 26.19 |
12/31/23 | 28.72 |
6/30/24 | 10.10 |
3/31/24 | 8.61 |
12/31/23 | 10.82 |
6/30/24 | 7.61 |
3/31/24 | 6.28 |
12/31/23 | 7.77 |
6/30/24 | 60.93 |
3/31/24 | 58.64 |
12/31/23 | 59.36 |
6/30/24 | 0.71 |
3/31/24 | 0.66 |
12/31/23 | 0.69 |
6/30/24 | 1.36 |
3/31/24 | 1.38 |
12/31/23 | 1.37 |
6/30/24 | 57.55 |
3/31/24 | 58.00 |
12/31/23 | 57.75 |